| Previous close | 1.6400 |
| Open | 1.1600 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 480.00 |
| Expiry date | 2024-12-20 |
| Day's range | 1.1600 - 3.0400 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksTMO's New ICP-MS Systems Boost Trace Element Analysis: Stock to Gain?
Thermo Fisher introduces the iCAP MX Series ICP-MS to simplify trace elemental analysis.
ZacksShould You Continue to Hold TMO Stock in Your Portfolio?
Thermo Fisher advances in its growth strategy, supported by its wave of innovations. However, macroeconomic issues escalate expenses.
ReutersExclusive-Thermo Fisher's plant making infant RSV drug breached FDA rules, documents show
(Reuters) -One of the largest contract drug manufacturing plants in the U.S. owned by Thermo Fisher Scientific over the past 10 years has repeatedly breached rules meant to ensure drugs are free of contamination, FDA documents show, including twice this year. The most recent U.S. Food and Drug Administration inspection of Thermo Fisher's Greenville plant in May identified manufacturing issues for the respiratory syncytial virus drug Beyfortus, a preventive antibody therapy from AstraZeneca and Sanofi for infants and toddlers. The issues were resolved to the FDA's satisfaction, the FDA and Sanofi said.
